TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01257165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Zopiclone pill 5 or 10 mg, given orally as a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 50 mg per 70 kg body weight, given orally as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill identical to zopiclone pill, given orally as a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill identical to zopiclone pill, given orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill identical to zopiclone pill, given orally as a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink, given orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Placebo drink, given orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Placebo drink, given orally as a single dose
Study: NCT01982760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: Patients Receiving DDAVP prior to operation
Study: NCT02726555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red yeast rice and atorvastatin
Description: Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin alone
Description: Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
Study: NCT02485795

Intervention type: OTHER
Intervention: Observational
Description: This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
Study: NCT02992665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca Ionophore A23187
Description: Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is used to control Ca ionophore group
Study: NCT01386216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magellan®
Description: Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
Study: NCT04300790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg tablets, twice daily, orally with breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg tablets, once daily, orally
Study: NCT00662038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone
Description: Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
Study: NCT00070122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study: NCT01606189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-2000-02
Description: Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
Study: NCT02731404

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HFJV ventilation
Description: The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IPPV ventilation
Description: The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
Study: NCT03431519

Intervention type: PROCEDURE
Intervention: VP
Description: Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation

Intervention type: PROCEDURE
Intervention: VP
Description: Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation
Study: NCT03691584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-6076
Description: The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage
Description: Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
Study: NCT04768790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary program
Description: multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
Study: NCT02841527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Description: Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
Study: NCT00006389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT04768790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General program
Description: exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
Study: NCT01133509

Intervention type: DRUG
Group type: OTHER
Intervention: Gardasil
Description: 0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
Study: NCT01643395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vertebroplasty
Description: Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse

Intervention type: OTHER
Group type: OTHER
Intervention: conservative therapy
Description: The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
Study: NCT05465694

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2-minute-time interval of per oral 24% sucrose
Description: Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no time interval of per oral 24% sucrose
Description: no time interval of per oral 24% sucrose
Study: NCT03459495

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic ultrasound
Description: Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo ultrasound
Description: When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
Study: NCT03460717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Field Stimulation by Thermal Micro-Cautery
Description: The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
Study: NCT06417645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed propofol infusion 15 mg/kg/h until 1% BSR (burst suppression ratio)
Description: after a slow induction with propofol to loss of consiousness (LOC), we proceed to give remifentanil TCI and rocuronium and intubate the patient. After 5 min we infuse 15 mg/kg/h until 1%BSR observe in the BIS monitor. Then we reduce the TCI LOC predicted concentration.
Study: NCT04668781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia via epidural catheter
Description: Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Analgesia via wound catheter
Description: Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
Study: NCT04146272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Power Hearing Aid Current
Description: The current power hearing aid used to treat strong hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Power Hearing Aid Current
Description: The current power hearing aid used to treat strong hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Power Hearing Aid New
Description: The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Power Hearing Aid New
Description: The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
Study: NCT00006389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00747890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified tonsillectomy
Description: * Tonsillectomy~* Uvulectomy~* Soft palatal resection~* Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle counselling by physician
Description: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
Study: NCT00126542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02425267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation (Physiotherapy)
Description: The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
Study: NCT00393627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education Program
Description: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Program
Description: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
Study: NCT02386371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumorectomy
Description: Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra Operative Radiotherapy
Description: After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
Study: NCT02135783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive Craniectomy
Description: A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-Decompressive Craniectomy
Description: a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
Study: NCT03610633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution.
Study: NCT02374502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: 'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
Study: NCT02519296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: 8 sessions with prolonged exposure therapy and fMRI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: fMRI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: fMRI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging of the brain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging of the brain
Study: NCT01126021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants are eligible for incentives if they participate in at least 30 games per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants are eligible for incentives if they participate in at least 30 games per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants are eligible for incentives if they participate in at least 30 games per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No incentives
Description: Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
Study: NCT01517022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy
Description: nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
Study: NCT03364816

Intervention type: PROCEDURE
Intervention: TDR
Description: total artificial disc replacement

Intervention type: PROCEDURE
Intervention: TDR
Description: total artificial disc replacement

Intervention type: PROCEDURE
Intervention: TDR
Description: total artificial disc replacement
Study: NCT02425267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation (Physiotherapy)
Description: The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
Study: NCT01419249

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
Study: NCT02362035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Orally Administered (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous Administered (IV)
Study: NCT03672539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04123366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Oral tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT00070122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03380325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Description: Iloprost is a stable prostacyclin analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Description: Iloprost is a stable prostacyclin analogue
Study: NCT00021541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
Study: NCT02355262

Intervention type: OTHER
Intervention: Informational Intervention
Description: Receive CATCH-UP intervention
Study: NCT04295928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPP
Description: Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation